Peptron, Inc. (087010.KQ)
KRW 98300.0
(-1.99%)
KRW 98300.0
(-1.99%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 4.86 Billion KRW | 16.3% |
| 2022 | 4.18 Billion KRW | -7.35% |
| 2021 | 4.51 Billion KRW | 107.69% |
| 2020 | -58.73 Billion KRW | -10038.37% |
| 2019 | 590.95 Million KRW | -97.32% |
| 2018 | 22.08 Billion KRW | 2026.25% |
| 2017 | 1.03 Billion KRW | 167.29% |
| 2016 | -1.54 Billion KRW | -196.92% |
| 2015 | 1.59 Billion KRW | -11.82% |
| 2014 | 1.8 Billion KRW | -77.36% |
| 2013 | 7.97 Billion KRW | 773.73% |
| 2012 | -1.18 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 7.33 Billion KRW | 50.64% |
| 2024 Q2 | 8.49 Billion KRW | 15.86% |
| 2023 Q3 | 2.36 Billion KRW | -8.88% |
| 2023 Q1 | 3.92 Billion KRW | -6.15% |
| 2023 Q2 | 2.6 Billion KRW | -33.81% |
| 2023 FY | 4.86 Billion KRW | 16.3% |
| 2023 Q4 | 4.86 Billion KRW | 105.46% |
| 2022 Q4 | 4.18 Billion KRW | 86.09% |
| 2022 Q3 | 2.24 Billion KRW | -51.52% |
| 2022 Q2 | 4.63 Billion KRW | -8.79% |
| 2022 FY | 4.18 Billion KRW | -7.35% |
| 2022 Q1 | 5.08 Billion KRW | 12.59% |
| 2021 Q4 | 4.51 Billion KRW | -15.12% |
| 2021 FY | 4.51 Billion KRW | 107.69% |
| 2021 Q2 | -8.19 Billion KRW | -200.67% |
| 2021 Q3 | 5.32 Billion KRW | 164.92% |
| 2021 Q1 | 8.14 Billion KRW | 125.36% |
| 2020 Q1 | 28.03 Billion KRW | 5.03% |
| 2020 Q4 | -32.11 Billion KRW | -207.23% |
| 2020 Q2 | 29.26 Billion KRW | 4.37% |
| 2020 Q3 | 29.95 Billion KRW | 2.35% |
| 2020 FY | -58.73 Billion KRW | -10038.37% |
| 2019 Q3 | 18.34 Billion KRW | -3.75% |
| 2019 Q2 | 19.06 Billion KRW | -13.79% |
| 2019 Q1 | 22.11 Billion KRW | 0.15% |
| 2019 FY | 590.95 Million KRW | -97.32% |
| 2019 Q4 | 26.69 Billion KRW | 45.48% |
| 2018 Q1 | 18.47 Billion KRW | 1679.22% |
| 2018 FY | 22.08 Billion KRW | 2026.25% |
| 2018 Q3 | 22.88 Billion KRW | -1.56% |
| 2018 Q2 | 23.24 Billion KRW | 25.8% |
| 2018 Q4 | 22.08 Billion KRW | -3.5% |
| 2017 Q3 | 157.77 Million KRW | 119.15% |
| 2017 Q4 | 1.03 Billion KRW | 558.21% |
| 2017 FY | 1.03 Billion KRW | 167.29% |
| 2017 Q1 | -660.89 Million KRW | 57.18% |
| 2017 Q2 | -823.83 Million KRW | -24.65% |
| 2016 Q2 | -2.52 Billion KRW | -300.7% |
| 2016 Q1 | 1.25 Billion KRW | -20.95% |
| 2016 FY | -1.54 Billion KRW | -196.92% |
| 2016 Q4 | -1.54 Billion KRW | -31.0% |
| 2016 Q3 | -1.17 Billion KRW | 53.36% |
| 2015 Q4 | 1.59 Billion KRW | -4.38% |
| 2015 Q2 | 1.59 Billion KRW | -9.35% |
| 2015 Q1 | 1.75 Billion KRW | 0.0% |
| 2015 FY | 1.59 Billion KRW | -11.82% |
| 2015 Q3 | 1.66 Billion KRW | 4.62% |
| 2014 Q1 | 626.7 Million KRW | 0.0% |
| 2014 FY | 1.8 Billion KRW | -77.36% |
| 2013 FY | 7.97 Billion KRW | 773.73% |
| 2012 FY | -1.18 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| HLB Co., Ltd. | -46.18 Billion KRW | 110.542% |
| iNtRON Biotechnology, Inc. | -40.58 Billion KRW | 111.996% |
| BINEX Co., Ltd. | 45.34 Billion KRW | 89.264% |
| Bioneer Corporation | -3.9 Billion KRW | 224.588% |
| Anterogen.Co.,Ltd. | 8.35 Billion KRW | 41.706% |
| MEDIPOST Co., Ltd. | 14.81 Billion KRW | 67.136% |
| CrystalGenomics, Inc. | 8.99 Billion USD | 45.855% |
| Helixmith Co., Ltd | -24.42 Billion KRW | 119.932% |
| Chabiotech Co.,Ltd. | 388.94 Billion KRW | 98.748% |
| Medy-Tox Inc. | 49.58 Billion KRW | 90.181% |
| Amicogen, Inc. | 125.26 Billion KRW | 96.113% |
| Genexine, Inc. | 61.39 Billion KRW | 92.07% |
| HLB Therapeutics Co.,Ltd. | -13.68 Billion KRW | 135.572% |
| LegoChem Biosciences, Inc. | -56.05 Billion KRW | 108.686% |
| ALTEOGEN Inc. | 53.56 Billion KRW | 90.912% |
| PharmaResearch Co., Ltd. | -32.93 Billion KRW | 114.781% |
| SillaJen, Inc. | -13.89 Billion KRW | 135.047% |
| JETEMA, Co., Ltd. | 84.27 Billion KRW | 94.223% |
| OliX Pharmaceuticals,Inc | 27.37 Billion KRW | 82.215% |
| Genomictree Inc. | -43.43 Billion KRW | 111.209% |
| MedPacto, Inc. | -64 Billion KRW | 107.607% |
| D&D Pharmatech | -7.5 Billion KRW | 164.848% |
| EASY BIO,Inc. | 53.21 Billion KRW | 90.85% |
| GI Innovation, Inc. | -4.82 Billion KRW | 200.956% |